Johnson & Johnson (JNJ) said Saturday that new longer follow-up results from the investigational phase 1b/2 study of amivantamab in combination with chemotherapy showed "encouraging" anti-tumor activity, durable responses, and low rates of treatment-related discontinuations in patients with a certain type of metastatic colorectal cancer.
The safety profile was consistent with previous reports of amivantamab plus chemotherapy in colorectal cancer.
The observations support further investigation in ongoing phase 3 studies in first- and second-line colorectal cancer, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments